AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

AZN MARCH 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

AstraZeneca PLC (LON:AZN) announced it has voluntarily withdrawn the use of Imfinzi in patients with locally advanced or metastatic bladder cancer in the US. The decision was made in consultation with the Food and Drug Administration (FDA).

AstraZeneca withdraws bladder cancer drug in US

European healthcare workers are asking to receive other vaccine doses due to AstraZeneca's lower efficacy, and reports of negative side effects.

European Healthcare Workers Are Refusing AstraZeneca Vaccine Over Efficacy Concerns

On Saturday, the Taiwanese government granted emergency authorization for use of AstraZeneca's and Oxford University's COVID-19 vaccine, with inoculations expected to start in the next fortnight, Reuters reported. Assuming the paperwork is in order, the first shots will be distributed within a week of arrival, Food and Drug Administration Director-General Wu Shou-mei told reporters.

Taiwan grants emergency AstraZeneca COVID-19 vaccine authorization and orders 10 million doses

Johnson & Johnson

The two big drugmakers' vaccine fortunes recently went in opposite directions.

Will AstraZeneca's Pain Be Johnson & Johnson's Gain?

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) from May 21, 2020 through November 20, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal securities laws.

AZN DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC– AZN

San Francisco, California--(Newsfile Corp. - February 18, 2021) - Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: May 21, 2020 - Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit: www.hbsslaw.com/investor-fraud/AZNContact An Attorney Now: AZN@hbsslaw.com 844-916-0895AstraZeneca PLC (AZN) Securities Fraud Class Action:The complaint alleges that Defendants misrepresented...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts AstraZeneca (AZN) Investors of Securities Fraud Case Related to Potential COVID-19 Treatment Filed, Filing Deadline Approaching

New York, New York--(Newsfile Corp. - February 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Breaking News: Rosen, Globally Respected Investor Counsel, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

BioNTech SE

Novavax

Pfizer

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Alphabet

GrowGeneration Corp

Forget about the Reddit rally stocks. This trio offers far better long-term growth prospects.

3 Markedly Better Stocks to Buy Than Sundial or AMC

Merck

Based on the planned interim analysis, the Independent Data Monitoring Committee (IDMC) has recommended that OlympiA Phase 3 trial evaluating AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) will move to early primary analysis and reporting. According to IDMC, the trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS).

AstraZeneca/Merck's PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

AZN DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

The move will allow the vaccine to be distributed through an effort the organization is leading to send doses to low-income countries.

World Health Organization Authorizes AstraZeneca's Covid-19 Vaccine

The COVID-19 vaccine developed jointly by AstraZeneca and the University of Oxford is being approved by a rising number of regulators, paving the way for its generalized use, notably in the developing world.

WHO and Australian approvals lift hopes for AstraZeneca vaccine

AstraZeneca stock was subject to wild swings in 2020 as the company pushed forward in developing a coronavirus vaccine. Now that the firm has authorization in the U.K., is AZN stock a buy?

Is AstraZeneca Stock A Buy After U.K., Europe Authorize Covid Vaccine?

The World Health Organization (WHO) listed two versions of the AstraZeneca Plc (NASDAQ: AZN) and Oxford University's COVID-19 vaccine for emergency use, thus widening the access to the shot in the developing countries and boost global supplies in the coming weeks.  The newly approved vaccines are produced by AstraZeneca-SKBio in South Korea and the Serum Institute of India.

WHO Grants Emergency Approval For AstraZeneca/Oxford COVID-19 Vaccine

The country has suspended the rollout of the shot which was found to be minimally effective in preventing mild disease against the more contagious South African variant.

Report: South Africa Asks Indian Maker Of AstraZeneca Vaccine To Take Back One Million Doses

NEW YORK, Feb. 15, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff...

BREAKING ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages AstraZeneca PLC Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - AZN

Here's what you need to know to navigate the markets today.

WHO Grants Emergency Use Approval for AstraZeneca Vaccine

The authorization could have a big impact on getting the vaccine to developing countries.

AstraZeneca/Oxford Covid-19 Vaccine Gets Emergency Approval From WHO

LOS ANGELES, Feb. 12, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities...

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

AstraZeneca PLC (LON:AZN) is on track to have COVID-19 vaccines targeting the new variants ready by autumn. In collaboration with the University of Oxford, the pharma giant is adapting the already approved and distributed jab to new disease strains, with clinical trials earmarked for the spring.

Coronavirus: AstraZeneca to prepare jabs against new variants by autumn

AstraZeneca PLC's (AZN) CEO Pascal Soriot on Q4 2020 Results - Earnings Call Transcript

AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.

AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes

Shares of AstraZeneca (NASDAQ:AZN) rose 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 20% year over year to $0.54, which missed the estimate of $0.68.

News for AstraZeneca Stock (AZN)